The antimicrobial resistance catastrophe is a growing global health threat and predicted to be worse in developing countries. Phages for Global Health (PGH) is training scientists in these regions to isolate relevant therapeutic phages for pathogenic bacteria within their locality, and thus contributing to making phage technology universally available.
Materials and Methods:
During the inaugural PGH workshop in East Africa, samples from Ugandan municipal sewage facilities were collected and two novel Escherichia coli lytic phages were isolated and characterized.
Results:
The phages, UP19 (capsid diameter ∼100 nm, contractile tail ∼120/20 nm) and UP30 (capsid diameter ∼70 nm, noncontractile tail of ∼170/20 nm), lysed ∼82% and ∼36% of the 11 clinical isolates examined, respectively. The genomes of UP19 (171.402 kb, 282 CDS) and UP30 (49.834 kb, 75 CDS) closely match the genera Dhakavirus and Tunavirus, respectively.
Conclusion:
The phages isolated have therapeutic potential for further development against E. coli infections.
Get full access to this article
View all access options for this article.
References
1.
Velazquez-MezaME, Galarde-LópezM, Carrillo-QuirózB, et al.Antimicrobial resistance: One Health approach. Vet World, 2022; 15(3):743–749; doi: 10.14202/vetworld.2022.743-749
2.
PrestinaciF, PezzottiP, PantostiA. Antimicrobial resistance: A global multifaceted phenomenon. Pathog Glob Health, 2015; 109(7):309–318; doi: 10.1179/2047773215y.0000000030
3.
O'NeillJ. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Philos Trans R Soc Lond B Biol Sci, 2015; 370(1670):20140082.
KariukiS, KeringK, WairimuC, et al.Antimicrobial resistance rates and surveillance in sub-Saharan Africa: Where are we now?. Infect Drug Resist, 2022; 15:3589–3609; doi: 10.2147/idr.S342753
6.
MoyoP, MoyoE, MangoyaD, et al.Prevention of antimicrobial resistance in sub-Saharan Africa: What has worked? What still needs to be done?. J Infect Public Health, 2023; 16(4):632–639; doi: https://doi.org/10.1016/j.jiph.2023.02.020
7.
El-ShibinyA, El-SahharS. Bacteriophages: The possible solution to treat infections caused by pathogenic bacteria. Can J Microbiol, 2017; 63(11):865–879; doi: 10.1139/cjm-2017-0030
8.
PrincipiN, SilvestriE, EspositoS. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol, 2019; 10:513; doi: 10.3389/fphar.2019.00513
9.
MakumiA, MhoneAL, OdabaJ, et al.Phages for Africa: The potential benefit and challenges of phage therapy for the livestock sector in sub-Saharan Africa. Antibiotics (Basel), 2021; 10(9):1085; doi: 10.3390/antibiotics10091085
10.
NagelTE, ChanBK, De VosD, et al.The developing world urgently needs phages to combat pathogenic bacteria. Front Microbiol, 2016; 7:882; doi: 10.3389/fmicb.2016.00882
11.
NagelT, MusilaL, MuthoniM, et al.Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world. Curr Opin Virol, 2022; 53:101208; doi: https://doi.org/10.1016/j.coviro.2022.101208
12.
NagelTE, MutaiIJ, JosephsT, et al.A brief history of phage research and teaching in Africa. PHAGE, 2022; 3(4):184–193; doi: 10.1089/phage.2022.29037.inp
NagelTE, ChanBK, NaleJY, et al.Phages as antibacterial agents: Laboratory training in developing countries. In: AMR Control 2018 Overcoming Global Antimicrobial Resistance (Carlet J, Upham G. eds.). Tim Probart; 2018:89–93. Available from: http://resistancecontrol.info/wp-content/uploads/2018/05/89-93.pdf [Last accessed: September13, 2023].
15.
van ZylLJ, AbrahamsY, StanderEA, et al.Novel phages of healthy skin metaviromes from South Africa. Sci Rep, 2018; 8(1):12265; doi: 10.1038/s41598-018-30705-1
16.
NaleJY, SpencerJ, HargreavesKR, et al.Bacteriophage combinations significantly reduce clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother, 2016; 60(2):968–981; doi: 10.1128/aac.01774-15
17.
MontsoPK, MlamboV, AtebaCN. Characterization of lytic bacteriophages infecting multidrug-resistant shiga toxigenic atypical Escherichia coli O177 strains isolated from Cattle Feces. Front Public Health, 2019; 7:355; doi: 10.3389/fpubh.2019.00355
18.
ChenS, ZhouY, ChenY, et al.FASTP: An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 2018; 34(17):i884–i890; doi: 10.1093/bioinformatics/bty560
19.
BushnellB. BBMap: A Fast, Accurate, Splice-Aware Aligner. Berkeley, CA; 2014. Available from: https://www.osti.gov/biblio/1241166 [Last accessed: September13, 2023].
20.
BankevichA, NurkS, AntipovD, et al.SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol, 2012; 19(5):455–477; doi: 10.1089/cmb.2012.0021
21.
GurevichA, SavelievV, VyahhiN, et al.QUAST: Quality assessment tool for genome assemblies. Bioinformatics, 2013; 29(8):1072–1075; doi: 10.1093/bioinformatics/btt086
22.
HockenberryAJ, WilkeCO. BACPHLIP: Predicting bacteriophage lifestyle from conserved protein domains. PeerJ, 2021; 9:e11396; doi: 10.7717/peerj.11396
23.
TerzianP, Olo NdelaE, GaliezC, et al.PHROG: Families of prokaryotic virus proteins clustered using remote homology. NAR Genom Bioinform, 2021; 3(3):lqab067; doi: 10.1093/nargab/lqab067
ShenA, MillardA. Phage genome annotation: Where to begin and end. Phage (New Rochelle), 2021; 2(4):183–193; doi: 10.1089/phage.2021.0015
26.
MoraruC, VarsaniA, KropinskiAM. VIRIDIC-a novel tool to calculate the intergenomic similarities of prokaryote-infecting viruses. Viruses, 2020; 12(11):1268; doi: 10.3390/v12111268
27.
RibeiroKVG, RibeiroC, DiasRS, et al.Bacteriophage isolated from sewage eliminates and prevents the establishment of Escherichia coli Biofilm. Adv Pharm Bull, 2018; 8(1):85–95; doi: 10.15171/apb.2018.011
28.
RossA, WardS, HymanP. More is better: Selecting for broad host range bacteriophages. Front Microbiol, 2016; 7:1352; doi: 10.3389/fmicb.2016.01352
Rogers Van KatwykS, HoffmanSJ, MendelsonM, et al.Strengthening the science of addressing antimicrobial resistance: A framework for planning, conducting and disseminating antimicrobial resistance intervention research. Health Res Policy Systems, 2020; 18(1):60; doi: 10.1186/s12961-020-00549-1
31.
DoffkayZ, DömötörD, KovácsT, et al.Bacteriophage therapy against plant, animal and human pathogens. Acta Biol Szegedien, 2015; 59:291–302.
32.
DedrickRM, Guerrero-BustamanteCA, GarlenaRA, et al.Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med, 2019; 25(5):730–733; doi: 10.1038/s41591-019-0437-z
33.
KassaT. Bacteriophages against pathogenic bacteria and possibilities for future application in Africa. Infect Drug Resist, 2021; 14:17–31; doi: 10.2147/idr.S284331
34.
KakabadzeE, MakalatiaK, GrdzelishviliN, et al.Selection of potential therapeutic bacteriophages that lyse a CTX-M-15 extended spectrum β-lactamase producing Salmonella enterica serovar typhi strain from the Democratic Republic of the Congo. Viruses, 2018; 10(4):172; doi: 10.3390/v10040172
35.
ZhvaniaP, HoyleNS, NadareishviliL, et al.Phage therapy in a 16-year-old boy with netherton syndrome. Front Med, 2017; 4:94; doi: 10.3389/fmed.2017.00094
36.
NaleJY, AhmedB, HaighR, et al.Activity of a bacteriophage cocktail to control Salmonella growth ex vivo in Avian, Porcine, and human epithelial cell cultures. PHAGE, 2023; 4(1):11–25; doi: 10.1089/phage.2023.0001
37.
KoskellaB, BrockhurstMA. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev, 2014; 38(5):916–931; doi: 10.1111/1574-6976.12072
38.
BullJJ, LevinBR, MolineuxIJ. Promises and pitfalls of in vivo evolution to improve phage therapy. Viruses, 2019; 11(12):1083; doi: 10.3390/v11121083
39.
BumunangEW, McAllisterTA, PoloRO, et al.Genomic profiling of non-O157 shiga toxigenic Escherichia coli-infecting bacteriophages from South Africa. PHAGE, 2022; 3(4):221–230; doi: 10.1089/phage.2022.0003
40.
TopkaG, BlochS, Nejman-FaleńczykB, et al.Characterization of bacteriophage vB-EcoS-95, isolated from urban sewage and revealing extremely rapid lytic development. Front Microbiol, 2019; 9:3326; doi: 10.3389/fmicb.2018.03326
41.
AghaeeBL, MirzaeiMK, AlikhaniMY, et al.Sewage and sewage-contaminated environments are the most prominent sources to isolate phages against Pseudomonas aeruginosa. BMC Microbiol, 2021; 21(1):132; doi: 10.1186/s12866-021-02197-z
42.
HymanP. Phages for phage therapy: Isolation, characterization, and host range breadth. Pharmaceuticals, 2019; 12(1):35.
43.
DebartolomeisJ, CabelliVJ. Evaluation of an Escherichia coli host strain for enumeration of F male-specific bacteriophages. Appl Environ Microbiol, 1991; 57(5):1301–1305; doi: 10.1128/aem.57.5.1301-1305.1991
44.
MuniesaM, BlanchAR, LucenaF, et al.Bacteriophages may bias outcome of bacterial enrichment cultures. Appl Environ Microbiol, 2005; 71(8):4269–4275; doi: 10.1128/aem.71.8.4269-4275.2005
45.
Van TwestR, KropinskiAM. Bacteriophage enrichment from water and soil. Methods Mol Biol, 2009; 501:15–21; doi: 10.1007/978-1-60327-164-6_2
46.
ŚliwkaP, Weber-DąbrowskaB, ŻaczekM, et al.Characterization and comparative genomic analysis of three virulent E. coli bacteriophages with the potential to reduce antibiotic-resistant bacteria in the environment. Int J Mol Sci, 2023; 24(6):5696.
47.
LiS, LuS, HuangH, et al.Comparative analysis and characterization of Enterobacteria phage SSL-2009a and ‘HK578likevirus' bacteriophages. Virus Res, 2019; 259:77–84; doi: https://doi.org/10.1016/j.virusres.2018.10.019
48.
DelesalleVA, TankeNT, VillAC, et al.Testing hypotheses for the presence of tRNA genes in mycobacteriophage genomes. Bacteriophage, 2016; 6(3):e1219441; doi: 10.1080/21597081.2016.1219441
49.
YangJY, FangW, Miranda-SanchezF, et al.Degradation of host translational machinery drives tRNA acquisition in viruses. Cell Systems, 2021; 12(8):771–779.e5; doi: https://doi.org/10.1016/j.cels.2021.05.019
50.
LinDM, KoskellaB, LinHC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther, 2017; 8(3):162–173; doi: 10.4292/wjgpt.v8.i3.162
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
